A Novel Liquid Biopsy Technique for Brain Tumor Diagnosis
By LabMedica International staff writers Posted on 27 Oct 2020 |

Image: Digital droplet PCR (ddPCR): schematic showing oil droplets containing fluorescent PCR target molecules (Photo courtesy of Wikimedia Commons)
A minimally invasive liquid biopsy technique enables diagnosis of glioma, the most common type of brain tumor, by PCR analysis of an easily obtained blood plasma sample.
Detection of TERT (Telomerase reverse transcriptase) promoter mutations (C228T, C250T) in circulating cell free DNA (cfDNA) has been successful for some systemic cancers but has not been demonstrated in gliomas, despite the high prevalence of these mutations in glioma tissue (they are in more than 60% of all gliomas and in 80% of all high-grade gliomas, the most aggressive and life-threatening type). The liquid biopsy approach for brain tumors is complicated, as brain tumor DNA is shed into the bloodstream at much lower levels than that of any other type of tumors.
To improve this situation, investigators at Massachusetts General Hospital (Boston, USA) developed a novel digital droplet PCR assay that incorporated features to improve sensitivity and allowed for the simultaneous detection and longitudinal monitoring of two TERT promoter mutations (C228T and C250T) in cfDNA from the plasma of glioma patients.
Droplet digital PCR (ddPCR) is a method of dPCR in which a 20 microliter sample reaction including assay primers and either Taqman probes or an intercalating dye, is divided into about 20,000 nanoliter-sized oil droplets through a water-oil emulsion technique, thermocycled to endpoint in a 96-well PCR plate, and fluorescence amplitude read for all droplets in each sample well in a droplet flow cytometer.
Results revealed that in baseline performance in tumor tissue, the assay had perfect concordance with an independently performed clinical pathology laboratory assessment of TERT promoter mutations in the same tumor samples. Extending to matched plasma samples, the investigators detected TERT mutations in both discovery and blinded multi-institution validation cohorts with an overall sensitivity of 62.5% and a specificity of 90% compared to the gold standard tumor tissue-based detection of TERT mutations. Upon longitudinal monitoring in five patients, they reported that peripheral TERT mutant allele frequency reflected the clinical course of the disease with levels decreasing after surgical intervention and therapy and increasing with tumor progression.
"Liquid biopsy is particularly challenging in brain tumors because mutant DNA is shed into the bloodstream at much lower level than any other types of tumors," said contributing author Dr. Leonora Balaj, investigator in neurosurgery at Massachusetts General Hospital. "By “supercharging” our ddPCR assay with novel technical improvements, we showed for the first time that the most prevalent mutation in malignant gliomas can be detected in blood, opening a new landscape for detection and monitoring of the tumors. The test is easy to use, quick, and low cost, and could be performed in most laboratories. Importantly, the test can also be used to follow the course of disease."
The glioma liquid biopsy paper was published in the October 13, 2020, online edition of the journal Clinical Cancer Research.
Related Links:
Massachusetts General Hospital
Detection of TERT (Telomerase reverse transcriptase) promoter mutations (C228T, C250T) in circulating cell free DNA (cfDNA) has been successful for some systemic cancers but has not been demonstrated in gliomas, despite the high prevalence of these mutations in glioma tissue (they are in more than 60% of all gliomas and in 80% of all high-grade gliomas, the most aggressive and life-threatening type). The liquid biopsy approach for brain tumors is complicated, as brain tumor DNA is shed into the bloodstream at much lower levels than that of any other type of tumors.
To improve this situation, investigators at Massachusetts General Hospital (Boston, USA) developed a novel digital droplet PCR assay that incorporated features to improve sensitivity and allowed for the simultaneous detection and longitudinal monitoring of two TERT promoter mutations (C228T and C250T) in cfDNA from the plasma of glioma patients.
Droplet digital PCR (ddPCR) is a method of dPCR in which a 20 microliter sample reaction including assay primers and either Taqman probes or an intercalating dye, is divided into about 20,000 nanoliter-sized oil droplets through a water-oil emulsion technique, thermocycled to endpoint in a 96-well PCR plate, and fluorescence amplitude read for all droplets in each sample well in a droplet flow cytometer.
Results revealed that in baseline performance in tumor tissue, the assay had perfect concordance with an independently performed clinical pathology laboratory assessment of TERT promoter mutations in the same tumor samples. Extending to matched plasma samples, the investigators detected TERT mutations in both discovery and blinded multi-institution validation cohorts with an overall sensitivity of 62.5% and a specificity of 90% compared to the gold standard tumor tissue-based detection of TERT mutations. Upon longitudinal monitoring in five patients, they reported that peripheral TERT mutant allele frequency reflected the clinical course of the disease with levels decreasing after surgical intervention and therapy and increasing with tumor progression.
"Liquid biopsy is particularly challenging in brain tumors because mutant DNA is shed into the bloodstream at much lower level than any other types of tumors," said contributing author Dr. Leonora Balaj, investigator in neurosurgery at Massachusetts General Hospital. "By “supercharging” our ddPCR assay with novel technical improvements, we showed for the first time that the most prevalent mutation in malignant gliomas can be detected in blood, opening a new landscape for detection and monitoring of the tumors. The test is easy to use, quick, and low cost, and could be performed in most laboratories. Importantly, the test can also be used to follow the course of disease."
The glioma liquid biopsy paper was published in the October 13, 2020, online edition of the journal Clinical Cancer Research.
Related Links:
Massachusetts General Hospital
Latest Molecular Diagnostics News
- Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
- Rapid Diagnostic Test to Halt Mother-To-Child Hepatitis B Transmission
- Simple Urine Test Could Help Patients Avoid Invasive Scans for Kidney Cancer
- New Bowel Cancer Blood Test to Improve Early Detection
- Refined Test Improves Parkinson’s Disease Diagnosis
- New Method Rapidly Diagnoses CVD Risk Via Molecular Blood Screening
- Blood Test Shows Promise for Early Detection of Dementia
- CRISPR-Based Diagnostic Test Detects Pathogens in Blood Without Amplification
- Portable Blood-Based Device Detects Colon Cancer
- New DNA Test Diagnoses Bacterial Infections Faster and More Accurately
- Innovative Bio-Detection Platform Improves Early Cancer Screening and Monitoring
- Blood Test Could Help More Women Survive Aggressive Triple Negative Breast Cancer
- CSF Test Distinguishes Prion Disease from Other Causes of Rapidly Progressive Dementia
- Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries
- CRISPR-Based Test Diagnoses Life-Threatening Fungal Infection More Quickly
- First Of Its Kind Measles Antibody Test Validated for Use with Dried Blood Spot Samples
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read moreCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreInnovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read morePathology
view channel
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
Philips and Ibex Expand Partnership to Enhance AI-Enabled Pathology Workflows
Royal Philips (Amsterdam, The Netherlands) has expanded its partnership with Ibex Medical Analytics (Tel Aviv, Israel) and released the new Philips IntelliSite Pathology Solution (PIPS) to further accelerate... Read more
Grifols and Inpeco Partner to Deliver Transfusion Medicine ‘Lab of The Future’
Grifols (Barcelona, Spain), a manufacturer of plasma-derived medicines and innovative diagnostic solutions, has entered into a strategic agreement with Inpeco (Novazzano, Switzerland), a global leader... Read more